Move to topTop

TOKYO, JAPAN - September 17, 2019 - Terumo Corporation (TSE: 4543) announced that it has launched fentanyl injection, a prescription-only analgesic, for Japanese healthcare providers today.

Janssen Pharmaceutical K.K. has marketed the product as a generic drug in Japan since 2009, while Piramal Critical Care acquired the product from Janssen Pharmaceutica NV in 2016. Terumo entered into an exclusive distribution partnership in Japan for the product with Piramal Critical Care in 2018. With the conclusion of the agreement, Terumo has proceeded to take over marketing authorization of the product from Janssen Pharmaceutical K.K.

Fentanyl is a prescription-only analgesic that is widely used for during- or post-operative pain management. Post-operative pain not only causes discomfort for patients, but also leads to delays in getting out of bed and prolonged hospitalization. Therefore, it is necessary to minimize pain and aim for early recovery after surgery.

Having designated pain management as an important business domain, Terumo also markets multiple products including an intravenous injection of acetaminophen. With the launch of the fentanyl injection and future expansion of its product portfolio, Terumo aims to contribute to alleviating patients' pain.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

News TOP